A Multi-center, Randomized, Double-blinded, Placebo-controlled Trial of Additive Effect of Duloxetine for Neuropathic Cancer Pain Refractory to Opioids and Gabapentinoids: JORTC- PAL08 (DIRECT study)

Hideaki Hasuo

[O7-3] A Multi-center, Randomized, Double-blinded, Placebo-controlled Trial of Additive Effect of Duloxetine for Neuropathic Cancer Pain Refractory to Opioids and Gabapentinoids: JORTC- PAL08 (DIRECT study)

Hideaki Hasuo¹, Hiromichi Matsuoka², Satoru Iwase³, Tempei Miyaji³, Takashi Kawaguchi³, Takuhiro Yamaguchi³, Keisuke Ariyoshi³, Shunsuke Oyamada³, Yoshinobu Matsuda⁴, Kazuki Tahara⁵, Eriko Satomi⁶ (1.Department of Psychosomatic Medicine, Kansai Medical University, 2.Department of Psychosomatic Medicine, Kindai University Faculty of Medicine, 3.Japanese Organisation for Research and Treatment of Cancer, 4.Department of Psychosomatic Internal Medicine and Supportive and Palliative Care Team, National Hospital. Organization Kinki-Chuo Chest Medical Center, 5.Palliative Care Center Nara Medical University, 6.Department of Palliative Medicine, National Cancer Center Hospital)

Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.

Presentation information

[O7] 痛みの評価・診断/オピオイド以外の薬物療法/その他の痛みに関するもの

[O7-3] A Multi-center, Randomized, Double-blinded, Placebo-controlled Trial of Additive Effect of Duloxetine for Neuropathic Cancer Pain Refractory to Opioids and Gabapentinoids: JORTC- PAL08 (DIRECT study)

Password